MARKET

SCYX

SCYX

Scynexis
NASDAQ
1.560
-0.030
-1.89%
Pre Market: 1.610 +0.05 +3.21% 04:00 11/30 EST
OPEN
1.570
PREV CLOSE
1.590
HIGH
1.630
LOW
1.550
VOLUME
1
TURNOVER
0
52 WEEK HIGH
3.870
52 WEEK LOW
1.150
MARKET CAP
58.04M
P/E (TTM)
1.115
1D
5D
1M
3M
1Y
5Y
Scynexis: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 1d ago
Scynexis: Notice of Effectiveness
Press release · 1d ago
Scynexis: Prospectus [Rule 424(b)(5)]
Press release · 2d ago
Weekly Report: what happened at SCYX last week (1120-1124)?
Weekly Report · 3d ago
The Slippery Slope Of Scynexis' Manufacturing Maze
We maintain our sell rating due to the company's voluntary recall of its flagship product, brexafemme. The recall has had a significant impact on scyx stock price and raises doubts over manufacturing challenges. Gsk biotech is a subsidiary of scynexis.
Seeking Alpha · 11/20 12:00
Weekly Report: what happened at SCYX last week (1113-1117)?
Weekly Report · 11/20 09:42
SCYNEXIS GAAP EPS of -$0.04, revenue of $1.8M
Scynexis reported q3 gaap eps of -$0.04, revenue of $1.8m. Scynexis is expected to report q3 results on november 14. The company has a market capitalization of $2.2 billion and a market value of $3.1 billion.
Seeking Alpha · 11/14 15:18
Strong Buy Recommendation for SCYNEXIS Biotech Amid Successful Antifungal Drug Development and Favorable Financial Performance
TipRanks · 11/14 12:56
More
About SCYX
SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. Its Ibrexafungerp has demonstrated activity against a large collection of medically relevant strains of Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera. The Company has received approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection), and for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), respectively.

Webull offers SCYNEXIS Inc stock information, including NASDAQ: SCYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCYX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SCYX stock methods without spending real money on the virtual paper trading platform.